3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pancreatic Neoplasms
10
Breast Neoplasms
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Melanoma
4
COVID-19
4
Multiple Myeloma
3
Lung Neoplasms
3
Colonic Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Solid Tumor
2
Recurrence
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Leukemia
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Urologic Diseases
1
Untreated Resectable Pancreatic Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Resectable Localized Prostate Cancer
1
Refractory or Relapsed Solid Tumors
1
Interventions
Cyclophosphamide
21
Cytarabine
15
blinatumomab
13
fludarabine
12
Azacitidine
10
venetoclax
9
fludarabine phosphate
9
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Rituximab
6
Mercaptopurine
6
Daunorubicin
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Etoposide
4
Busulfan
4
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasm, Residual
×
Hydroxychloroquine
×
Clear all
NCT04841148
2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
96 enrolled